Cambridge's TRIMTECH brings Seed round to €41M as J&J and BGF back its brain-penetrant protein degraders

Cambridge-based TRIMTECH Therapeutics has added a €12 million ($14 million) tranche to its Seed financing, co-led by Johnson & Johnson Innovation – JJDC, Inc. and BGF. The new money takes the company's total Seed round to €41 million ($47 million), with existing investors Cambridge Innovation Capital and SV Health Investors' Dementia Discovery Fund also backing the platform.

A different way to attack neurodegeneration

The diseases TRIMTECH is aiming at — Alzheimer's foremost among them — share a hallmark: the brain accumulates misfolded protein aggregates that the cell's own clean-up machinery can no longer clear. Most drugs try to block a target. TRIMTECH instead wants to remove it, using targeted protein degraders: small molecules that tag a disease-causing protein for destruction by the cell's disposal system.

Its platforms, branded TRIMTAC and TRIMGLUE, are built around TRIM21, an E3 ligase — an enzyme that marks proteins for degradation. Harnessing TRIM21 to drag toxic aggregates into the cell's recycling pathway is the scientific core of the company, which was founded in 2023 by Leo James of the MRC Laboratory of Molecular Biology and Will McEwan of the UK Dementia Research Institute at the University of Cambridge — two researchers whose work sits at exactly that intersection.

The blood-brain barrier problem

There is a reason so few degrader programmes target the brain: the blood-brain barrier. Most such molecules are large and struggle to cross it, which is precisely where Alzheimer's drugs need to act. TRIMTECH's emphasis on a portfolio of CNS-penetrant (central-nervous-system-penetrant) degraders is the company's attempt to solve the delivery problem alongside the biology — and it is the focus the new funding is meant to advance. CEO Dr Nicki Thompson framed the tranche as fuel to "forge ahead with developing our portfolio of CNS penetrant degraders based on our unique platforms."

A strategic investor at Seed

The most telling detail is the lead. JJDC, the corporate venture arm of Johnson & Johnson, co-leading a Seed extension is unusual — strategic pharma money typically arrives later, once a platform is further de-risked. Its presence this early reads as a bet on the underlying science rather than a near-term asset.

TRIMTECH remains early-stage, preclinical platform work — there are no late-trial readouts here, and neurodegeneration has humbled far better-funded efforts. But a €41 million Seed with J&J's venture arm at the table buys an unusually long runway to find out whether brain-penetrant degraders can do what blocking-based drugs have not.